Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tiragolumab - Genentech

X
Drug Profile

Tiragolumab - Genentech

Alternative Names: anti-TIGIT - Roche; MTIG-7192A; RG-6058; RG6058-10; RG6058-11; RO 7092284

Latest Information Update: 09 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Chugai Pharmaceutical; Genentech; National Cancer Institute (USA); Roche; Washington University School of Medicine
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Liver cancer; Non-small cell lung cancer; Oesophageal cancer
  • Phase II Cervical cancer; Gastric cancer; Malignant melanoma; Rectal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Phase I/II B-cell lymphoma
  • No development reported Multiple myeloma; Triple negative breast cancer

Most Recent Events

  • 09 May 2024 Phase- I development is ongoing in Solid-tumours (Late-stage disease, Metastatic disease, Combination therapy) in South Korea, France, Canada, Spain, Japan, Australia (IV) (NCT02794571) (Roche pipeline, May 2024)
  • 09 May 2024 Roche plans regulatory filings in Liver cancer (First line therapy, Combination therapy) in or after 2027 (Roche pipeline, May 2024)
  • 09 May 2024 Roche plans to file a regulatory application for Squamous cell cancer (Combination therapy, First-line therapy, Metastatic disease, Recurrent) in or after 2027 (Roche pipeline, May 2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top